141 related articles for article (PubMed ID: 37277194)
1.
Meng XY
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37277194
[No Abstract] [Full Text] [Related]
2. Response to "
Aizenbud L; Schoenfeld DA; Caulfield JI; Mann JE; Austin MR; Perdigoto AL; Herold KC; Kluger HM
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349129
[No Abstract] [Full Text] [Related]
3. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.
Caulfield JI; Aizenbud L; Perdigoto AL; Meffre E; Jilaveanu L; Michalek DA; Rich SS; Aizenbud Y; Adeniran A; Herold KC; Austin MR; Kluger H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898736
[TBL] [Abstract][Full Text] [Related]
4. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
[TBL] [Abstract][Full Text] [Related]
5. Re: Germline Variants Associated with Toxicity to Immune Checkpoint Blockade.
Jones JO; Mitchell TJ; Stewart GD
Eur Urol; 2023 Dec; 84(6):597. PubMed ID: 36964039
[No Abstract] [Full Text] [Related]
6. Review - The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors.
de Joode K; Heersche N; Basak EA; Bins S; van der Veldt AAM; van Schaik RHN; Mathijssen RHJ
Cancer Treat Rev; 2024 Jan; 122():102662. PubMed ID: 38043396
[TBL] [Abstract][Full Text] [Related]
7. NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.
Yoshihama S; Cho SX; Yeung J; Pan X; Lizee G; Konganti K; Johnson VE; Kobayashi KS
Sci Rep; 2021 Feb; 11(1):3258. PubMed ID: 33547395
[TBL] [Abstract][Full Text] [Related]
8. Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.
Montaudié H; Beranger GE; Reinier F; Nottet N; Martin H; Picard-Gauci A; Troin L; Ballotti R; Passeron T
Pigment Cell Melanoma Res; 2021 Sep; 34(5):978-983. PubMed ID: 33449414
[TBL] [Abstract][Full Text] [Related]
9. Multitumor Case Series of Germline
Kinget L; Bechter O; Punie K; Debruyne PR; Brems H; Clement P; Roussel E; Van Herck Y; Albersen M; Baldewijns M; Schöffski P; Beuselinck B
Curr Oncol; 2021 Aug; 28(5):3227-3239. PubMed ID: 34449592
[TBL] [Abstract][Full Text] [Related]
10. Using germline genotype in cancer pharmacogenetic studies.
McWhinney SR; McLeod HL
Pharmacogenomics; 2009 Mar; 10(3):489-93. PubMed ID: 19650256
[TBL] [Abstract][Full Text] [Related]
11. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
12. Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.
Trabelsi Grati O; Zemoura L; Nhy C; Daniel C; Melaabi S; Callens C; Gauthier Villars M; Bièche I; Girard N
Lung Cancer; 2022 Dec; 174():186-187. PubMed ID: 36156246
[TBL] [Abstract][Full Text] [Related]
13. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
O'Donnell PH; Ratain MJ
Mol Oncol; 2012 Apr; 6(2):251-9. PubMed ID: 22321460
[TBL] [Abstract][Full Text] [Related]
14. Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy.
Catalano C; da Silva Filho MI; Jiraskova K; Vymetalkova V; Levy M; Liska V; Vycital O; Naccarati A; Vodickova L; Hemminki K; Vodicka P; Weber ANR; Försti A
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):838-842. PubMed ID: 29762254
[TBL] [Abstract][Full Text] [Related]
15. Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab.
Kiyomiya M; Fukuda K; Shimazu K; Yoshida T; Taguchi D; Shinozaki H; Nanjyo H; Shibata H
Jpn J Clin Oncol; 2023 Mar; 53(3):270-274. PubMed ID: 36484308
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomic Germline Testing: Applications in Oncology Nursing.
Germany J; Kueber J
Clin J Oncol Nurs; 2023 Mar; 27(2):129-133. PubMed ID: 37677833
[TBL] [Abstract][Full Text] [Related]
17. Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC.
Qu J; Jiang M; Wang L; Zhao D; Qin K; Wang Y; Tao J; Zhang X
Biomed Pharmacother; 2020 Jul; 127():109996. PubMed ID: 32388240
[TBL] [Abstract][Full Text] [Related]
18. The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer.
Fan Y; Ying H; Wu X; Chen H; Hu Y; Zhang H; Wu L; Yang Y; Mao B; Zheng L
Cancer Biol Med; 2020 Nov; 17(4):1002-1013. PubMed ID: 33299649
[TBL] [Abstract][Full Text] [Related]
19. Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?
Sobhani N; Corona SP; Roviello G; Bagby S; D'Angelo A; Iezzi G; Generali D
Future Oncol; 2020 Jul; 16(19):1327-1330. PubMed ID: 32396404
[No Abstract] [Full Text] [Related]
20. Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors.
Refae S; Gal J; Ebran N; Otto J; Borchiellini D; Peyrade F; Chamorey E; Brest P; Milano G; Saada-Bouzid E
Invest New Drugs; 2020 Feb; 38(1):160-171. PubMed ID: 31402427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
